key: cord-0765999-vuxxo1o9
authors: Whitmore, Hannah A.B.; Kim, Leo A.
title: Understanding the Role of Blood Vessels in the Neurological Manifestations of COVID-19
date: 2021-06-11
journal: Am J Pathol
DOI: 10.1016/j.ajpath.2021.04.017
sha: 70a68a4e209101e96584f15185a38f58996ef728
doc_id: 765999
cord_uid: vuxxo1o9

SARS-CoV-2 was originally identified as an outbreak in Wuhan, China towards the end of 2019 and quickly became a global pandemic, with a large death toll. Originally identified as a respiratory disease, similar to previously discovered SARS and MERS type viruses, concern has since been raised about the effects of SARS-CoV-2 infection on the vasculature. This viral-vascular involvement is of particular concern with regards to the small vessels present in the brain, with mounting evidence demonstrating that SARS-CoV-2 is capable of crossing the blood-brain-barrier. Severe symptoms of infection, termed COVID-19, often result in neurological complications, regardless of patient age. These neurological complications range from mild to severe across all demographics, however, the long-term repercussions of neurological involvement on patient health are still unknown.

Currently, there are approximately 140 million confirmed infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) worldwide, and about 3,000,000 deaths associated with SARS-CoV-2 infection (https://coronavirus.jhu.edu, accessed 04/17/2021) manifesting as severe coronavirus disease 2019, or COVID-19. Approximately 15% of individuals affected by COVID-19 develop severe disease, and 6% are critically ill, resulting in respiratory failure and/or multiple organ dysfunction or failure. 1 The original outbreak of SARS-CoV-2 infection originated from Wuhan, Hubei province, China in late 2019. 2, 3 Genomic characterization indicates that bats and rodents are the likely gene sources of alpha-and beta-CoVs while gamma-and delta-CoVs likely arise from avian sources. 4 To date, seven human coronaviruses have been identified with the ability to cause respiratory, enteric, hepatic and neurological diseases in different animal species, including cattle and cats. These viruses are responsible for about 5-10% of acute respiratory infections, including the common cold. 4, 5 SARS-CoV-2 is a member of the beta coronaviruses and is closely related to severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) with high sequence homology. 6 These coronaviruses appear to infect the respiratory and gastrointestinal tract with patients presenting symptoms of fever, cough, and shortness of breath, while less common symptoms include diarrhea, vomiting and nausea. 7 In addition, cytokine release syndrome was found to be the major cause of morbidity in patients infected with SARS-CoV and MERS-CoV. 8 Aside from the respiratory system, with acute respiratory distress syndrome (ARDS) affecting roughly 1/3 of COVID-19 hospitalized patients, 9 COVID-19 appears to also involve multiple organ systems with pathological manifestations including the heart, kidney, and brain. [10] [11] [12] [13] [14] Due to the multi-organ involvement of COVID-19 it has been hypothesized that COVID-19 is a vascular disease that primarily affects endothelial cells. 15, 16 These organs, and their associated blood vessels, may be affected by direct viral tissue injury and localized disordered cytokine release. 17 This direct injury and release of inflammatory and apoptosis inducing mediators leads to localized microvascular inflammation, which triggers endothelial activation, leading to vasodilation and pro-thrombotic conditions, which cause increased patient mortality. 18 Viral infections of the brain are less common than those of other organs as the blood-brain barrier must be penetrated. Several viruses, including polio and West Nile are able to cause neurological complications, but the reasons why less than 1 in 100 patients are affected in this way are not understood. 19 It is believed that the route of entry of the virus into the brain, such as in the blood supply or by direct infection of vascular endothelial cells, plays a role in the number and type of neurological symptoms presented by the patient. 19, 20 Investigations into MERS-CoV indicated that viral particles enter the bloodstream and are able to infect endothelial cells. 21 In the J o u r n a l P r e -p r o o f case of SARS-CoV-2, viral-like particles have been seen in brain capillary endothelium and actively budding across endothelial cells. 22 Although the route of entry of the virus may still be unknown, recent publications have highlighted neurological manifestations which have been observed in 42% of COVID-19 patients at disease onset, 63% during hospitalization, and 82% at some time during the course of the disease. 23, 24 Additionally, a significant link was seen between magnetic resonance (MRI) abnormalities and persistent neurological deficits which continued 3 months after disease onset in 55% of patients. 23 In this review we will consider the role of the vasculature specifically within the context of the neurological manifestations of COVID-19. We will review the neurological manifestations that have been reported with SARS-CoV-2 infection. Then, we will examine the evidence that suggests blood vessels are involved in SARS-CoV-2 infection. Finally we consider the multiple pathological processes (thromboembolic, inflammatory, and secondary processes) within blood vessels that may contribute towards the neurological manifestations of COVID-19 infection.

Coronaviruses are related in structure as well as replication mode and the relatedness of Human CoVs to the neurotropic animal coronaviruses is predictive of the ability of SARS-CoV-2 to invade the central nervous system (CNS), suggesting some tropism for neural tissue. 22, 25-29 SARS-CoV-2 has a particularly strong affinity for the ACE2 receptor, which it attaches to via its spike protein. 17, 30 The ACE2 receptor is ubiquitous across several organ systems, including the lungs, heart and kidney, but the expression of ACE2 in the brain is significantly lower than that of other organs. 30, 31 However, in an in vitro model of the human BBB, the function of the BBB is negatively affected by the SARS-CoV-2 spike protein and brain endothelial cells showed a distinct pro-inflammatory response when exposed to the spike protein. 32 Therefore, the virus must likely overcome the blood-brain barrier (BBB), which plays a critical role in CNS homeostasis, and provides a fundamental level of protection from microorganisms and viruses. 33- 35 The BBB is composed of the endothelial cells (ECs) that line blood vessels, as well as pericytes, astrocytes, neurons and the extracellular matrix. 35 Specifically, the interaction between ECs and pericytes within a common basal lamina via "peg and socket" junctions, as well as the direct encasing of retinal capillaries by astrocytic endfeet and microglia, form the neurovascular unit. 35 Further, the ECs in particular, within the CNS, form a tight barrier via continuous tight junctions, lack of fenestration, and low pinocytic activity drastically limiting the transport of molecules between the vascular system and the CNS. 34 J o u r n a l P r e -p r o o f

Despite the presence of this barrier, the CNS can be reached by some viruses that can infect neurons and glial cells. 28 Although experimental evidence regarding SARS-CoV-2 neuroinvasiveness is still lacking, there is evidence obtained through post-mortem studies which indicate that the virus has reached the brain microvasculature, cerebrospinal fluid as well as the neurons. 36 This may in part be due to the fact that not all blood vessels within the CNS are composed of the cellular constituents of the neurovascular unit, and the integrity of the BBB varies throughout some portions of the CNS, such as the choroid plexus or the circumventricular organs, allowing for secretion of CSF and other neurosecretory functions. 20, 37 Thus, there is heterogeneity within CNS regions with respect to the barrier function of the BBB. 38 SARS-CoV has been shown to be both neuroinvasive and neurotropic, and due to the similarities between coronaviruses, it is highly likely that SARS-CoV-2 is similar with regards to these functions. 28 Neuronal retrograde dissemination as well as hematogenous dissemination could be potential pathways for SARS-CoV-2 to enter the central nervous system (CNS). Neuronal retrograde dissemination uses a protein called dynein to move viruses along the axon in the retrograde direction, from synapse to soma. 39 This is known to occur in viral infections such as HIV, where it contributes to viral latency. 29 The proposed route of retrograde viral transport originates at the nasal cavity, the site of the mild SARS-CoV-2 neurological symptom anosmia, 40 and ends at the brainstem, as follows: nasal cavity > olfactory nerve > olfactory bulb > piriform cortex > brainstem. 30, 41 Another proposed route of infection involves endothelial cells and leukocyte trafficking. While in a healthy state the CNS is devoid of leukocytes, 42 in an inflammatory setting such as a viral infection, the infection can be established in the CNS by taking advantage of leukocyte trafficking. 43 This process may involve direct infection of cerebral vascular endothelial cells due to leukocyte tethering, which allows immediate passage across the BBB into the CNS. 20, 44 In addition to leukocyte activation and the trafficking of infected leukocytes through the blood-brain, the blood-CSF barrier may also be utilized as a hematogenous dissemination route, whereby infected hematopoietic cells are used as "Trojan horses" to transport virus into the CNS via the blood supply. 20, 28, 43 A systemic viral infection can also lead to inflammation-induced breakdown of the BBB, allowing viruses to slip through literal cracks between endothelial cells and into the CNS. 20, 28, 43 Although the activation, inflammation and immune response of endothelial cells may be enough to compromise the blood brain barrier (BBB) alone, it is also hypothesized that the actions of the matrix metalloproteinases (MMP) family of proteins may play a role in BBB integrity loss. MMP proteins are specifically relevant to BBB integrity, and upregulation by SARS-CoV-2 spike protein has been shown to significantly upregulate many of these key proteins. 32 This highly specific, localized pro-inflammatory response may offer a route for SARS-CoV-2 to breach the BBB. 32 The heterogeneity of barrier function within the CNS may additionally explain some of the variability of neurological manifestations of COVID-19.

Small Blood Vessel Disease in the Brain Theme Issue

Patients with severe respiratory disease have been reported to have multiple neurological manifestations. In a case study of 509 consecutive patients admitted with confirmed COVID-19 in Chicago, a significantly higher risk of neurological complications was seen in patients with severe symptoms of COVID-19. 23 Many of the coronaviruses discovered to date have similar structures and infection mechanisms as well as similar neuro-invasive potential. 28, 45 The neuroinvasiveness of SARS-CoV has been established previously, and due to the similarities between the two coronaviruses, a similar risk of neuro-invasiveness may be extrapolated to SARS-CoV-2. 22, 25-30, 36, 45 It has been previously reported that the coronavirus family, including SARS-CoV-2, has been associated with seizures, status epilepticus, encephalitis, acute disseminated encephalomyelitis, Guillan-Barre syndrome, leukoencephalopathy, and critical illness neuromyopathy. 46, 47 More recently, (in 2003) SARS-CoV was detected in the cerebrospinal fluid of a patient with SARS. 48, 49 While coronaviruses, including SARS-CoV-2, have been isolated from brain tissue in autopsy specimens, the presence of neutralizing antibodies in patient serum and cerebrospinal fluid has also been detected. 22, 33, 50 With respect to COVID-19, multiple neurological manifestations have been reported with SARS-CoV-2 infection with neurological findings reported to vary from non-specific to specific symptoms. 51 Reports of mild neurological symptoms include headache, dizziness, hypogeusia, hyposmia, and neuralgia. 52, 53 The underlying mechanisms of these neurological effects are likely numerous, including direct transmission through the olfactory nerve, 40 hypoxic brain injury, or immune mediated, via disruption of the blood-brain barrier. 32 Although the likely early symptoms of COVID-19, include a fever and headache, with approximately 11% of emergency room presenting patients suffering from headache. 51 As headaches are a common neurological response to many daily concerns including stress, tension and dehydration, 54 the presentation of this symptom is widely variable and cannot be taken alone, although poor response to common analgesics is common. 53 Patients have reported headaches as pulsating, stabbing or pressing which normally indicates different headache types such as migraine or tension. In the context of COVID-19, headache is likely to occur in conjunction with gastro-intestinal symptoms. 53 The significance of these dual symptoms of GI tract involvement with headache has been hypothesized as being linked to the "gut-brain axis". The gut-brain axis is affected by significant cytokine release, common in COVID-19 patients, 17, 18, 55 including TNF-, interleukins and calcitonin gene-related peptide (CGRP), a neuropeptide which is significantly linked to trigeminovascular activation, which leads to headache. 53 Further neurological complications and cerebrovascular events include cerebrovascular accident, Guillian-barre syndrome, acute transverse myelitis, and although difficult to detect, acute encephalitis. 14, 46 Encephalitis, or inflammation of the brain, is known to occur after some viral infections, including varicella zoster and influenza A viruses. 56 Coronaviruses have been detected in both cerebrum and cerebrospinal fluid of individuals with seizures, encephalitis, and encephalomyelitis. The first case of encephalitis associated with SARS-CoV-2 infection was reported in May 2020 in a 24 year old man 57 and since then, many more cases have been identified. 58 Case studies have identified that the higher risk of neurological complications in patients with severe symptoms is caused primarily by a higher frequency of encephalopathy, especially in older patients. 14, 23 Patients diagnosed with encephalitis have demonstrated signs of immune-mediated small-vessel damage, leading to altered integrity of the blood-brain barrier and brain edema. 59 Secondary central nervous system (CNS) vasculitis is a rare condition characterized by inflammation of the blood vessels in the brain or spine caused by viral infection, leading to varied symptoms including confusion and significant forgetfulness. 60 Due to its rarity, very few patients diagnosed with COVID-19 have exhibited symptoms and been included in case studies as confirmed vasculitis patients. The condition often presents as multiple ischemic small vessel lesions and hyperdense blood areas with scans showing injury to the intracranial microvasculature. 27, 60 The pattern seen on the scans has been reported to be characteristic of disease processes that progress from endoluminal, vessel wall (vasculitis), or perivascular (leukoencephalopathy) cellular proliferation. 27 Of the few case studies available, patients were treated with steroids and immunoglobulin, as well as interleukin inhibitors, with varied outcomes for the patients. 26, 60, 61 An increased rate of ischemic stroke and intracerebral hemorrhage have been reported among COVID-19 patients. 62, 63 Cerebrovascular accident, also known as stroke, is associated with COVID-19 diagnosis, across all age ranges, but is especially concerning in younger patients (< 50 years) without the expected risk factors. 12 Viral infections have been previously published as to cause strokes by increasing the risks for embolism. 13, 64 Hypercoagulopathy, resulting from viral effects on systemic and CNS coagulation pathways, has been a growing concern, and anticoagulant administration was reported to be associated with decreased mortality in COVID-19 patients. In a case study of 32 critically ill patients, 8 had severe CNS involvement. Three patients were imaged with vessel wall sequence MRI and showed contrast enhancement, suggesting large vessel pathologies with an inflammatory component, however CSF samples were negative for SARS-CoV-2. 11 There have since been reports that PCR analysis of the CSF may be not reliable for the diagnosis since SARS-CoV-2 dissemination in the brain can be transient and its CSF titer may be extremely low. 65 Across the published papers available by mid-2020, it was calculated that between 0.2 and 1% of those infected with COVID-19 develop ischemic strokes. 11 This compares to annual rates of roughly 0.1% of the population in the UK and 0.2% in the US. In stroke associated with a COVID-19 diagnosis, both the presentation and outcome are generally worse compared to other strokes. 12 Patients whose symptoms included severe pneumonia and multi-organ failure were more likely to additionally develop stroke and the outcome for these patients was poor. 66, 67 Reported cerebrovascular events are predominantly found in older patients, however, acute mental state alterations, while represented in all age groups, are considered to be disproportionately found in younger patients. 24, 68 Additional, long term studies are required, but there is also speculation that COVID-19 infection may have long term negative implications on the incidence of Alzheimer's disease within the population. 69 Disrupted cardiorespiratory function causes metabolic dysfunction that may increase risk for future Alzheimer's disease and related dementia, while the extreme inflammatory response to the infection causes the release of interleukins and TNF-α. 70 Proinflammatory cytokine expression promotes oxidative stress, which if unchecked, degrades mitochondria, causes DNA mutations, and accelerates apoptosis. 71 This cell death may lead to neural dysfunction and an acceleration in neural decline over time. 70 These data on the impact of the CNS insult to patients supports the fact that the neurologic complications from SARS-CoV-2 infection may have longer lasting consequences and in fact be more debilitating than the initial respiratory symptoms of the disease. 26

As COVID-19 mainly presents as a respiratory disease, it is not surprising that post-mortem studies in patients with COVID-19 identified diffuse alveolar damage in patients with severe disease, indicating pulmonary epithelial cell involvement. 72 However, several studies also describe severe endothelial damage and coagulopathic features in the pulmonary microvasculature (Fig. 1) . 18, 72 Human brain microvascular endothelial cells are known to be infected by several virus types including HIV, polio and SARS-CoV-2. 62, 73-75 Viral migration into the brain occurs in several ways, including tight junction modulation, 73 receptor activation 75 , hematogenous dissemination 28, 34 and direct endothelial cell infection. 74 Like many other viruses, the mechanisms underlying cerebral endothelial susceptibility and individual patient neurological responses to SARS-CoV-2 are unknown. 19, 62 Endothelial cells in a healthy environment are able to prevent coagulation, inhibit inflammation and control blood flow and the passage of proteins from blood into tissues by modulation of vascular permeability. 76, 77 Evidence based on COVID-19 risk factors which include old age, obesity, hypertension and diabetes mellitus, indicates a link between endothelial cells and COVID-19, as all of the above are characterized by pre-existing vascular dysfunction. 77 As J o u r n a l P r e -p r o o f endothelial cells play a crucial role in maintaining hemostasis and vessel wall integrity, localized dysfunction of pulmonary microvascular cells is likely to be a key component in the thromboinflammatory processes which result in COVID-19 vasculopathy. 78 There is evidence from autopsies that direct viral tissue injury and localized cytokine release induces microvascular inflammation, which triggers endothelial activation. 18 This has been seen in several organs, including the lungs 79 and kidneys. 10 The lungs of COVID-19 autopsy patients have features of severe endothelial injury associated with intracellular SARS-CoV-2 virus and disrupted endothelial cell membranes. 72, 79 The lungs have also been found to contain widespread vascular thrombosis with microangiopathy and occlusion of alveolar capillaries, 72 while the kidneys show evidence of vasodilation and pro-thrombotic conditions, 18 as well as cell swelling and capillary occlusion. 10 There is also significant evidence of heart damage, seen in upwards of 1/3 of hospitalized COVID-19 patients. 80 Co-morbidities of severe COVID-19, which are linked to vascular endothelial damage, such as atherosclerosis, cause significant damage to the endothelial glycocalyx, while SARS-CoV-2 can induce cytokine release, also leading to systemic degradation of the vascular endothelial glycocalyx. 81 This causes microvascular leakage and initiates changes in the coagulation cascade. 81, 82 Micro-thrombosis of the small vessel myocardial vasculature is a relatively common finding in COVID-19 patients and may persist even after viral clearance. 80 Further evidence of vascular cell involvement in coagulopathy, most obviously seen in thrombi formation in the lungs and in ischemic strokes, is also visible in the blood vessels of the skin. Rashes, described as livedoid and purpuric, are visible manifestations of a suspected underlying pulmonary thrombotic state in COVID-19 patients. 83 These rashes have been noted to occur in patients already receiving therapeutic dose anti-coagulation therapies to stave off suspected pulmonary embolism. 83 It is speculated that these symptoms are associated with occlusive vascular disease, 84 especially as punch biopsies indicated pauci-inflammatory thrombogenic vasculopathy involving capillaries, venules, and/or arterioles in conjunction with significantly elevated D -dimer levels. In these cases, patients were not believed to be suffering with alternate conditions resulting in thrombi formation, including disseminated intravascular coagulation (DIC), due to their normal levels of fibrinogen. 83 It is important to note that disruption of the endothelial cells is not an endpoint in itself, but rather a component of a thromboinflammatory feedback loop within small vessels, wherein disruption, cytokine release and coagulation cascade activation, lead to a comparably hypoxic environment which exacerbates the aforementioned factors. 78 Although in the lungs, thrombotic complications are likely to relate at least in part to endothelial inflammation and injury, evidence for this in the cerebrovascular system is currently limited. 61

Cytokine release syndrome, also described as cytokine storm, is of serious concern in COVID-19 patients as it has been linked to increased patient mortality. 8, 17, 18, 55 Viral infection leads to the release of anti-viral cytokines, such as IFN-αβ. 8 This leads to the release of pro-inflammatory cytokines such as TNF- and interleukins IL-6 and IL-1, as well as chemokines including VEGF, MCP-1 and CXCL10. 8, 17, 55 Although the relative levels of these cytokines is well below those found in ARDS patients for example, 18 they are far above normal and their presence in COVID-19 patients is now being used as biomarkers and predictors of future care. 23, 85 For example, IL-6 expression is significantly higher in fatal outcomes compared to survivors and is also used an indicator of the need for mechanical ventilation. 85 The activated phenotype of endothelial cells, which is induced by inflammatory cytokines and chemokines, promotes adhesions and infiltration of neutrophils, which produce large amounts of histotoxic mediators, including neutrophil extracellular traps (NETs) which leads to endothelial cell injury. 77 These activated endothelial cells initiate coagulation by expressing fibrinogen, among others, leading to platelet binding, fibrin production and thrombus formation. 86 The microvascular inflammation caused by release of inflammatory and apoptosis-inducing mediators, followed by endothelial activation, leads to increased patient mortality. 18 The main SARS-CoV-2 cellular receptor, ACE2, has regional variability within the human brain but is considered to be poorly expressed by human brain endothelial cells. 23, 62 Upregulation of ACE2 in the brain has been linked to oxidative stress, apoptosis and neurodegeneration. 23 A recent article demonstrated that ACE2 expression can be triggered in vitro in a flow-dependent manner, which indicates that cerebral vessels are susceptible to SARS-CoV-2 infection. 62 However, the question remains as to whether the pathobiology and neuroinfectiveness of SARS-CoV-2 means that damage occurs from direct effects of the virus on the CNS tissue, or whether damage occurs as a secondary insult, triggered by hypoxia, immune response cytokine release or clotting cascades. 23 Within the CNS, one proposed route of infection is direct infection of cerebral vascular endothelial cells due to leukocyte tethering and trafficking, 43 which allows immediate passage across the BBB into the CNS. 20, 44 Autopsied patients have been shown to have SARS-CoV-2 infected frontal lobe microvascular endothelial cells and tissue damage, characterized by cell lysis and dysfunction, as well as evidence of localized cytokine release, 18, 77 a probable cause of the prevalence of vessel inflammation seen in scans. 11 Interestingly, although ACE2 receptor is required for SARS-CoV-2 to bind and gain access to the cell, this binding reduces ACE2 enzyme activity, activating the kallikrein-bradykinin pathway and increasing vascular permeability. 77 J o u r n a l P r e -p r o o f This increased permeability leads to the release of inflammatory cytokines such as interleukins and TNF- whose downstream mediators promote fluid retention leading to increased vascular leakage. 76, 77 Likely cofactors remain a mystery however, in our understanding of the association of SARS-CoV-2 infection with cerebrovascular events.

While considered a mild symptom, headache caused by SARS-CoV-2 infection, is attributed to a possible pathophysiological mechanism involving the peripheral trigeminal nerve endings. It is hypothesized that this occurs either by direct viral activation or through vasculopathy caused by increased circulating pro-inflammatory cytokines and hypoxia. 53, 54 With regards to the rare neurologic symptoms, including encephalitis and vasculitis, immune-mediated small-vessel damage, leading to altered integrity of the blood-brain barrier followed by brain edema is the proposed mechanism. 59 In patients with vasculitis, this immune-mediated small vessel damage leads to ischemic lesions, as well as hyperdense blood areas, due to intracranial microvasculature injury. 27, 60 Immune related COVID-19 pathology in pediatric populations was recently described in the United States and in Europe. These children developed a Kawasaki-like syndrome, believed to be associated with COVID-19. 87 Kawasaki disease is characterized by a high fever and systemic vasculitis and may result in neurological complications. 30 In patients diagnosed with COVID-19, both ischemic and hemorrhagic strokes are possible, although hemorrhagic strokes are less likely. 66, 88 The rate of patients suffering with ischemic stroke is significantly elevated over the normal population. 46 Hypotheses as to the mechanism of action for both ischemic and hemorrhagic stroke onset include disseminated intravascular coagulation (DIC; also known as consumption coagulopathy) 89 as well as significantly increased levels of D-dimer. 2, 18 Rates of COVID-19 complicated by DIC has been reported as 0.6% for survivors and 71.4% for non-survivors. 89 Although most patients suffer from ischemic stroke, some patients suffer secondary hemorrhagic transformations of ischemic strokes. 88, 90, 91 This transition is indicative of serious malfunctions in both the clotting cascade, possibly due to DIC, as well as lack of integrity of the vessel walls caused by endothelial damage. 88, 91 This immunedriven endothelial damage is likely a large contributor to the increased risk of ischemic and hemorrhagic stroke seen in COVID-19 patients. 66 Additionally, hypercoagulability and vasculitis due to intracranial cytokine storm, leading to macro and micro thrombi formation in the vessels are also proposed as mechanisms. 11, 13, 92 

The large number of studies relating to COVID-19 (an early January 2021 PubMed search returned over 85,000 "COVID-19" hits), indicates the urgency in the scientific community to determine the factors causing increased patient mortality. While improving patient survival rates is of the utmost importance, the impact of the endothelium-linked CNS insult to COVID-19 J o u r n a l P r e -p r o o f patients cannot be overstated. Research articles discussing "Long COVID" and "Post-COVID-19 Neurological Syndrome" have been recently published. 93, 94 As the pandemic is still ongoing, it is too early to describe the future clinical needs of these patients, but current evidence would indicate that the long-term neurologic complications from SARS-CoV-2 infection may be more debilitating than the initial respiratory symptoms of the disease. 26, 69, 70, 93 

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a

Cases From the Chinese Center for Disease Control and Prevention

Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation

Clinical features of patients infected with 2019 novel coronavirus in

Ocular tropism of coronavirus (CoVs): a comparison of the interaction between the animal-to-human transmitted coronaviruses (SARS-CoV-1, SARS-CoV-2, MERS-CoV, CoV-229E, NL63, OC43, HKU1) and the eye

MERS, SARS and other coronaviruses as causes of pneumonia

Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China

SARS and MERS: recent insights into emerging coronaviruses

Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology

Incidence of ARDS and outcomes in hospitalized patients with COVID-19: a global literature survey

Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China -Kidney International

Large and Small Cerebral Vessel Involvement in Severe COVID-19

Cerebrovascular disease in COVID-19: Is there a higher risk of stroke? Brain, Behavior, & Immunity -Health

COVID-19 presenting as stroke

COVID-19 and the Brain: Acute Encephalitis as a Clinical Manifestation

COVID-19 is, in the end, an endothelial disease

COVID-19 -A vascular disease

Cytokine release syndrome in severe COVID-19

Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. The Lancet Respiratory Medicine

Viral diseases of the central nervous system. Current Opinions in Virology

Emerging human middle East respiratory syndrome coronavirus causes widespread infection and alveolar damage in human lungs

Blood Biomarkers for Detection of Brain Injury in COVID-19 Patients

Frequent neurologic manifestations and encephalopathy-associated morbidity in Covid-19 patients

Cerebrovascular Disease in Patients with COVID-19: A Review of the Literature and Case Series

COVID-19 Vasculitis: A Case Report with Complicated Course

COVID-19 Neurologic Complication with CNS Vasculitis-Like Pattern

Neuroinvasive and neurotropic human respiratory coronaviruses: potential neurovirulent agents in humans

Retrograde Axon Transport of Herpes Simplex Virus and Pseudorabies Virus: a Live-Cell Comparative Analysis

Multiple Neuroinvasive Pathways in COVID-19

SARS-CoV-2 Infectivity and Neurological Targets in the Brain

The SARS-CoV-2 spike protein alters barrier function in 2D static and 3D microfluidic invitro models of the human blood-brain barrier

Novel insights into the development and maintenance of the blood-brain barrier

Functional morphology of the blood-brain barrier in health and disease

Potential neuroinvasive pathways of SARS-CoV-2: Deciphering the spectrum of neurological deficit seen in coronavirus disease-2019 (COVID-19)

Sensory circumventricular organs in health and disease

Heterogeneity of the blood-brain barrier. Tissue Barriers

SARS-CoV-2 and nervous system: From pathogenesis to clinical manifestation

Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19

SARS-CoV-2: A new virus but a familiar inflammation brain pattern. Brain, Behavior, & Immunity

Chemotactic factors in cerebrospinal fluid during bacterial meningitis

Leukocyte-facilitated entry of intracellular pathogens into the central nervous system

Endothelial activation: intracellular signaling pathways

The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients

Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? The Lancet

Severe Acute Respiratory Syndrome Coronavirus 2-Induced Neurological Complication

Detection of SARS coronavirus RNA in the cerebrospinal fluid of a patient with severe acute respiratory syndrome

Possible central nervous system infection by SARS coronavirus

Two coronaviruses isolated from central nervous system tissue of two multiple sclerosis patients

Neurologic Characteristics in Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis

Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study

Headache characteristics in COVID-19 pandemic-a survey study

COVID-19 is a Real Headache! Headache

How COVID-19 induces cytokine storm with high mortality

Viral encephalitis: causes, differential diagnosis, and management

A first case of meningitis/encephalitis associated with SARS-Coronavirus-2

Meningoencephalitis associated with COVID-19: a systematic review

COVID-19-Associated PRES-like Encephalopathy with Perivascular Gadolinium Enhancement

Cerebral nervous system vasculitis in a Covid-19 patient with pneumonia

Immunosuppression for intracranial vasculitis associated with SARS-CoV-2: therapeutic implications for COVID-19 cerebrovascular pathology

Flow-Mediated Susceptibility and Molecular Response of Cerebral Endothelia to SARS-CoV-2 Infection

Neurologic Features in Severe SARS-CoV-2 Infection

Recent bacterial and viral infection is a risk factor for cerebrovascular ischemia

Encephalitis as a clinical manifestation of COVID-19. Brain, behavior, and immunity

Stroke in patients with SARS-CoV-2 infection: case series

The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management

Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study

The chronic neuropsychiatric sequelae of COVID-19: The need for a prospective study of viral impact on brain functioning

COVID-19 as a risk factor for Alzheimer's disease and related dementia: A perspective from Detroit, MI

Pathways to Brain Aging and Their Modifiers: Free-Radical-Induced Energetic and Neural Decline in Senescence (FRIENDS) Model -A Mini-Review

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

West Nile virus infection modulates human brain microvascular endothelial cells tight junction proteins and cell adhesion molecules: Transmigration across the in vitro blood-brain barrier

Human immunodeficiency virus infection of human brain capillary endothelial cells occurs via a CD4/galactosylceramideindependent mechanism

Poliovirus entry into human brain microvascular cells requires receptor-induced activation of SHP-2

Evolving functions of endothelial cells in inflammation

COVID-19: the vasculature unleashed

Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia The

Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer -Journal of Thoracic Oncology

COVID-19-Associated Nonocclusive Fibrin Microthrombi in the Heart

Endothelial glycocalyx damage as a systemic inflammatory microvascular endotheliopathy in COVID-19

Vascular endothelial injury exacerbates coronavirus disease 2019: The role of endothelial glycocalyx protection

Livedoid and Purpuric Skin Eruptions Associated With Coagulopathy in Severe COVID-19

Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases

Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19

Immunity, endothelial injury and complement-induced coagulopathy in COVID-19

COVID-19 and Kawasaki Disease: Novel Virus and Novel Case

Mechanisms of Stroke in COVID-19

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Acute Ischemic and Hemorrhagic Stroke and COVID-19: Case Series

Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Ischemic Stroke

COVID-19 and stroke, a case series and review of literature

Post-COVID 19 Neurological Syndrome (PCNS); a novel syndrome with challenges for the global neurology community

Long-COVID': a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19

We would like to thank Michel Plantevin for his generous support of this publication. We also thank Mr. Andrew Firger for his assistance and encouragement to make this work possible. Hannah A.B. Whitmore would like to personally thank the Consular Information Unit and the Nonimmigrant Visa Unit at the U.S. Embassy in London for their assistance in obtaining a National Interest Exemption Waiver to allow her return to the U.S. during the COVID-19 pandemic to work on this project. Leo A. Kim would like to personally thank Dr. Nahyoung Grace Lee for her extraordinary encouragement and support to make this work possible.